Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Rankning i aktier #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Aktiekurs
$17.64
Marknadsvärde
$32.65B
Förändring (1 dag)
-3.24%
Förändring (1 år)
-23.70%
Land
JP
Handel Daiichi Sankyo Company, Limited (DSNKY)

Kategori

Rörelsemarginal för Daiichi Sankyo Company, Limited (DSNKY)
Rörelsemarginal per March 2026 TTM: 13.90%
Enligt de senaste finansiella rapporterna och aktiekursen för Daiichi Sankyo Company, Limited är företagets nuvarande rörelsemarginal (TTM) 13.90%. Vid slutet av 2024 var rörelsemarginalen 11.50%.
Historik för rörelsemarginal för Daiichi Sankyo Company, Limited från 2000 till 2026
Rörelsemarginal vid slutet av varje år
År Rörelsemarginal Ändra
2026 (TTM) 13.90% -13.56%
2025 16.08% 39.83%
2024 11.50% 43.93%
2023 7.99% -42.85%
2022 13.98% 5.43%
2021 13.26% -53.10%
2020 28.27% 56.97%
2019 18.01% 13.34%
2018 15.89% -14.66%
2017 18.62% -29.58%
2016 26.44% 63.31%
2015 16.19% 21.64%
2014 13.31% 32.17%
2013 10.07% -3.73%
2012 10.46% -17.18%
2011 12.63% 25.92%
2010 10.03% -4.93%
2009 10.55% -40.80%
2008 17.82% 21.47%
2007 14.67% -12.21%
2006 16.71% 15.64%
2005 14.45% -9.80%
2004 16.02% 14.35%
2003 14.01% -4.63%
2002 14.69% -8.81%
2001 16.11% -33.43%
2000 24.20% 0.00%
Rörelsemarginal för liknande företag eller konkurrenter
Företag Rörelsemarginal Skillnad i rörelsemarginal Land
45.56% -96.72%
US
23.28% -98.33%
GB
27.17% -98.05%
US
26.72% -98.08%
US
31.24% -97.75%
CH
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.